Case guide

Past Zantac use: which records help a review?

Keep papers that identify the drug, cancer and any earlier case. Mark gaps and uncertain dates.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202614 sources

This may apply to you if

  • Preparation suggestions only; no cancer list, use-duration threshold or current firm acceptance rule is verified.
  • Describe the product, dates and diagnosis you want checked.
  • Ask a lawyer what evidence and court route apply to your own situation.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

Robin L. Rosenberg · United States District Court, Southern District of Florida · District judge signing order 81

Finding: The February 2023 order distinguishes five designated cancers from other injuries and recalls prior federal expert-evidence rulings. Its scope does not decide every state claim.

Federal court: February 14, 2023 Zantac order 81 (opens in a new tab) · Feb 14, 2023 · Checked Oct 4, 2026

The evidence and its limits

Yonsei University College of Medicine, first-author affiliation · JAMA Network Open · 2023

Ranitidine Use and Incident Cancer in a Multinational Cohort

Design:
Cohort
Participants:
1,183,999 eligible people across eleven analytical databases: 909,168 new ranitidine users and 274,831 other H2-blocker users. Primary meta-analysis used four databases meeting stricter balance criteria.
Finding:
The primary and broader comparisons did not show a statistically significant overall cancer increase relative to other H2 blockers.
Main limitation
Prescription or dispensing data do not capture all actual or nonprescription use; individual impurity and dietary exposure were not measured. Follow-up may miss long-latency effects and rare or small differences. The paper reports distinct primary, broader and calibrated estimates; no pooled number is presented as one universal eleven-database result. No individual cause or universal safety finding.

Read the source: Ranitidine Use and Incident Cancer in a Multinational Cohort (opens in a new tab) · Checked Oct 4, 2026

The short answer

Which medicine details should I look for?
Look for the active ingredient, maker, strength and dispensing dates. Keep the original record or label if you have it. Do not fill missing details with guesses. [13]
How can I ask for missing health records?
Ask the provider how to get covered copies. The access rule includes some health records and has exceptions. It does not give every helper access to every file. [3]
What if a nonprescription purchase has no receipt?
Describe what you recall and mark the uncertainty. Do not invent a purchase or a use period to match a claimed acceptance rule. [6]
Which cancer papers should I prepare?
Keep the cancer and care reports you lawfully hold. Ask which records show where the cancer started and how it was found. [3]

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

Keep papers that identify the drug, cancer and any earlier case. Mark gaps and uncertain dates. A pharmacy record describes use; it does not prove drug cause or a right to payment.

Which medicine details should I look for?

Look for the active ingredient, maker, strength and dispensing dates. Keep the original record or label if you have it. Do not fill missing details with guesses.

The Zantac 360 label names famotidine, unlike older ranitidine. A familiar brand name alone cannot identify every purchase. Mark whether a detail comes from a record or from memory.

How can I ask for missing health records?

Ask the provider how to get covered copies. The access rule includes some health records and has exceptions. It does not give every helper access to every file.

Specify the relevant visits and date range as a preparation step. Ask how a representative can establish authority and keep any denial or missing-file response. Access rights do not certify a medicine-use history.

What if a nonprescription purchase has no receipt?

Describe what you recall and mark the uncertainty. Do not invent a purchase or a use period to match a claimed acceptance rule.

The 2023 study notes that prescribing or dispensing data can miss actual and nonprescription use. That limitation does not prove your own purchases; it explains why a records check should preserve gaps rather than hide them.

Which cancer papers should I prepare?

Keep the cancer and care reports you lawfully hold. Ask which records show where the cancer started and how it was found.

The federal order distinguishes five cancer types and other injuries for its evidence process. A product record and a disease report answer different questions; neither by itself supplies the required scientific proof.

What dates and prior case papers matter?

Give the lawyer medicine, cancer and earlier filing dates. Ask which law and claim set the limit. Do not pick one national cutoff.

A recall posting date does not calculate every personal deadline. Include existing court papers and agreements, with uncertain dates clearly marked. Ask whether a date is a case-management requirement or a filing rule for you.

Does gathering records prove that I have a claim?

No. A file can support a review without deciding cause or acceptance. Ask the lawyer what proof and court issues still need assessment.

The 2023 study’s population result does not establish personal exposure or individual cause. The federal order also requires defined scientific evidence for its covered cases. Organizing papers is a preparation step, not a promise of payment.

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Sources

  1. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  2. Southern District of New York: time limitsSouthern District of New York: time limits · court
  3. 45 CFR 164.524: access to health records45 CFR 164.524: access to health records · regulator
  4. FDA: April2020 ranitidine withdrawal requestFDA: April2020 ranitidine withdrawal request · regulator
  5. FDA: reformulated ranitidine approvalFDA: reformulated ranitidine approval · regulator
  6. You: original multinational ranitidine cancer cohortYou: original multinational ranitidine cancer cohort · study
  7. Wang: original Taiwan ranitidine cohortWang: original Taiwan ranitidine cohort · study
  8. Jones: April14,2026 Delaware Zantac orderJones: April14,2026 Delaware Zantac order · court
  9. Jones: January29,2026 Delaware time-limit rulingJones: January29,2026 Delaware time-limit ruling · court
  10. GSK announced agreements with 10 plaintiff firms representing ~80,000 claimants (93% of pending US state-court Zantac cases) to pay up to $2.2 billion in aggregate, with full implementation expected by end of H1 2025; GSK admitted no liability. GSK also agreed to pay $70 million to resolve the Valisure qui tam complaint. Verified from GSK's own press statement.us.gsk.com · Oct 9, 2024
  11. Sanofi agreed to pay more than $100 million to settle ~4,000 Zantac cancer suits in state courts outside Delaware — the first major resolution in the litigation, averaging more than $25,000 per claim per Bloomberg's reporting (republished by Insurance Journal, Apr 23, 2024; deal announced earlier that month). Sanofi denied liability; 70,000+ suits then remained, mostly in Delaware.insurancejournal.com · Apr 23, 2024 · study
  12. MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) omnibus Daubert order (Doc 6120, 341 pages): ALL defendants' Daubert motions on general causation GRANTED and defendants' summary judgment motion GRANTED — plaintiffs 'fail to produce admissible primary evidence of general causation' that ranitidine causes cancer, ending the federal MDL claims. Verified from the court order itself.gsk.com · Dec 6, 2022 · court
  13. DailyMed: Zantac 360 famotidine label
  14. Federal court: February 14, 2023 Zantac order 81Federal court: February 14, 2023 Zantac order 81 · court

Checked against 11 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026